Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06988618 · ClinicalTrials.gov registry record
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
A clinical trial of Prurigo Nodularis, sponsored by Galderma R&D.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT06988618 is a study of Prurigo Nodularis that is actively recruiting participants, run by Galderma R&D. The registered enrollment target is 600 participants, above the 187-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (221% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT06988618, a study of Prurigo Nodularis, is actively recruiting participants, sponsored by Galderma R&D.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
Conditions Studied
Study Locations (20)
Florida
- Galderma Investigational Site # 7087 - Coral Gables
- Galderma Investigational Site # 7063 - Cutler Bay
- Galderma Investigational Site # 7078 - Miami
- Galderma Investigational Site # 7070 - North Miami Beach
- Galderma Investigational Site # 7091 - Tampa
California
- Galderma Investigational Site # 7074 - Corona
- Galderma Investigational Site # 6836 - Fountain Valley
- Galderma Investigational Site # 8224 - Fremont
- Galderma Investigational Site # 7064 - Santa Monica
Arizona
- Galderma Investigational Site # 7077 - Phoenix
- Galderma Investigational Site # 7060 - Phoenix
- Galderma Investigational Site # 7067 - Tucson
Maryland
- Galderma Investigational Site # 8012 - Glendale
- Galderma Investigational Site # 7068 - Rockville
Alabama
- Galderma Investigational Site # 8893 - Birmingham
Colorado
- Galderma Investigational Site # 7061 - Castle Rock
Connecticut
- Galderma Investigational Site # 7059 - Fairfield
Illinois
- Galderma Investigational Site # 7058 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-08-11 |
| Est. Completion | 2027-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06988618
The ClinicalTrials.gov registry entry for NCT06988618 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 187-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (221% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 0 interventions.
NCT06988618 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06988618 about?
NCT06988618 is a clinical study titled "Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults". The main aim of this study is to assess real-world effectiveness of nemolizumab in Prurigo nodularis (PN) as measured by investigator and patient reported outcome (PRO) in clinical practice at Month 6.
What is the current status of trial NCT06988618?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2025-08-11. Estimated completion is 2027-11-30.
What conditions does trial NCT06988618 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
Who is sponsoring clinical trial NCT06988618?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06988618 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
Upadacitinib for Prurigo Nodularis
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
ACTIVE NOT RECRUITING
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.